On the 24th of August 2001, a group of business and licensing executives united in Basel and founded the Swiss Pharma Licensing Group. The first Board defined objectives, recruited members and set up the foundation for today’s association.
Both Swiss HLG and PCLF invited speakers from both countries to share with the audience their successes and above all how partnering influenced success.
Once again, attendance was a real success with around 130 delegates from Switzerland, France, Germany and other European countries.
The conference started with an insightful introduction from Patrick Aebischer, President emeritus, Brain Mind Institute at EPFL, on critical components and factors to build a successful innovation ecosystem between universities, research institutes, tech transfer offices, accelerator, and entrepreneurship.
Following the opening keynote, we had a series of inspiring presentations held by Jurgi Camblong (CEO of SOPHiAGENETICS), Mondher Majoubi (CEO of Innate Pharma), Hervé Affagard (CEO MaaT Pharma), Andreas Emmenegger (CFO of Molecular Partners). Beyond great insights on their promising technologies, participants could learn how they embraced partnering as a cornerstone strategy for the development of their company.
The event closed after a great panel moderated by Marc Ceulemans (Head of Strategic Investment from Novartis), with Michele Ollier (Partner atMedixci), Christoph Kausch (Partner at MTIP), Jean-Philippe Tripet (Partner at Aravis) and Marie Petit (Principal at Villiger Valuation) which touched on various topics such as cultural differences when building and financing start-ups between Europe and the US; key success factors for a start-up, and financing challenges in some countries.
Last but not least, for the first time, we interviewed some of our speakers, and we will be pleased to share their insights very soon.
Please find below some images from the conference. (Please click on the image to view it in its entirety and or a slide show.)
The Swiss Healthcare Licensing Group and the Pharma Licensing Club France are delighted to invite you to an event featuring key success stories of innovative companies in Switzerland and France. Companies active in the field of microbiome, immuno-oncology, digital and virtual reality or data analysis will address some of the key challenges they faced during the innovation, financing and deal-making processes.
Along with our partners Pharma Licensing Club France, we have prepared a great line up of distinguished speakers. They will discuss the topic: “INNOVATION IN HEALTHCARE: FROM TECHNOLOGY TO BUSINESS MODELS AND TRANSACTIONS.”
This exciting one day conference will be held on May 16th, 2018, at the Novartis Campus, Basel in Switzerland.
Come and join us, for an informative day which is not only an excellent platform for networking with colleagues but also a good place to showcase and attract partners to your organization.
Registration cost: including Networking Lunch & Breaks
Swiss HLG Member/PLCF Member Rate € 130
Non-Member Rate € 150
the number of seats/attendees is limited, register now!
Register now >> https://swisshlg.ngaevents.co.uk/swisshlg-basel/
We look forward to seeing you there.
The EPLC and Swiss HLG are delighted to invite you to the 14th International Pharmaceutical Licensing Symposium; Peak Performance. To be held in Montreux, Switzerland, 19th – 21st September 2018.
This year the EPLC have put together a program with the theme of Peak Performance designed to help you evolve your deal making in an ever-changing Business Development environment.
Why you should register
Who should attend
Business Development Executives, General Managers, Directors, Owners, Executives in Marketing, Regulatory & Finance from the Healthcare sector, from all countries
Basel, 16th February 2018 – The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 27th Conference titled “ Reset Partnering – Step out of the Box!” With partnering deals increasing in complexity, the evolution from pharmaceuticals to solutions and the consumerization of healthcare, Business Development, and Licensing professionals need to ask themselves if the tools and approaches used are still fit for purpose in the healthcare world of 2018.
Over three days, more than 100 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and exchange on the future of partnering and to take a step out of the Box.
Conference Director, Chris Isler with the active support of the entire Swiss HLG Board, convened a global panel of leading experts from the healthcare and consumer industry addressing three main questions:
Before the start of the conference, Anthony A. Hörning, CEO of Strategic Transactions Advisor and former head of Alliance Management at Novartis led a dynamic and interactive workshop helping participants to understand “What happens after marriage – managing complex alliances”.
As an introduction, Jean-Paul Clozel, CEO of Idorsia and former CEO of Actelion, brilliantly set the stage with his thought-provoking keynote speech on his company has been acquired by Johnson & Johnson, despite not willing himself to sell it. He brought the audience to think on how the relationship and trust dimension were important to make such a transaction a success.
Francesco De Rubertis, CEO of the Medicxi Venture Fund expanded on Clozel’s thoughts with the view from the VC’s perspective and explained how entrepreneurialism and venture capital could go hand in hand. He shared his opinion as VC vs JP Clozel vision as an entrepreneur.
One of the Swiss HLG objectives is not just professional but also personal development, and hence Design Thinking Master, Rana Lonnen, Head Search and Evaluation Strategic Venture Capital at Novartis Pharma opened the day on Monday exploring how design thinking approaches can be leveraged in a partnering setting.
Six captivating presentations illustrated then what, along with the partnering process, is required to find the right deal. Alan Selby, Executive Director at Torreya Partners, shared his thoughts on when to use a broker or not. Emma Barton, Director Alliance, and Integration Management at AstraZeneca explained how Outlicensing can preserve the value of a molecule. Shigeo Taniuchi, Head of EMEA, Senior Corporate officer at Santen Pharmaceutical and Viren Mahurkar, formerly at Alcon took a look at the cultural dimension of partnerships and what to bear in mind when working with partners in Japan or China.
Tanja Dowe, CEO of the Debiopharm Innovation Fund focused on how to find the right deal with a VC fund and last but not least Vikalp Mohan, Vice President Sales and Marketing at Celonic took a look at how to partner with a Contract Development and Manufacturing Organization.
After a full day of presentations, the delegates enjoyed a short walk and typical Swiss Fondue Dinner in a barn and used the opportunity to expand their personal and professional networks.
The last day of the conference focused on how to partner beyond the molecules, starting with a case study looking at how to make more out of data by Dr. Alexandra V. Eberhard, Managing Director Europe, and Executive VP Sciences at Signals Analytics. Michael Meissner, Chief Technology Officer, at Sanofi took a look at how technology is becoming increasingly important for pharma and asked the question if pharma in this picture is the boiling frog. Ravi Sodha, Senior Director, Business Development at Actelion closed this block in sharing his perspectives on what makes deals for rare diseases different.
The closing keynote, delivered by Jon Otterstatter, CEO of the Preventice Solutions Group took the audience along the journey of building a highly successful medical technology start-up from scratch to a 500+ employee organization with prominent investors such as Merck Inc or Boston Scientific.
The Swiss HLG Board thanks the presenters and the participants for the lively discussion and interactions. Please find below some images from the conference. (Please click on the image to view it in its entirety and or a slide show.)